



October 24, 2024

To,

BSE Limited
25, P. J. Towers,
Dalal Street,
Mumbai - 400 001
Scrip Code: 500120

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra – Kurla Complex, Bandra (E)
Mumbai – 400 051
Symbol: DIAMINESQ

Sub: Disclosure of Regulation 32(1) of The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter ended on September 30, 2024.

Dear Sir/Ma'am,

Pursuant to the Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company hereby confirms, that the Company has passed the Special resolution on August 01, 2024 for the Issue of not exceeding 9,16,390 (Nine Lakh Sixteen Thousand Three Hundred Ninety) convertible warrants at a price of ₹ 552/- (Rupees Five Hundred Fifty-Two only) each to the promoter/promoter group of the Company and certain identified non - promoter persons / entities by way of preferential allotment and has not raised any funds through other public issue, rights issue, QIP, etc. during the Quarter ended on September 30, 2024.

Hence, the statement of deviation or variation in public issue, rights issue, preferential issue, etc. under Regulation 32(1) of The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter ended on September 30, 2024, is enclosed herewith.

Kindly take the above mentioned information on records.

Thanking You,

Yours Faithfully,
For Diamines and Chemicals Limited

Hemaxi Pawar
Company Secretary
Membership No.: A52581
Encl: As above



Statement of Deviation / Variation in utilisation of funds raised						
Name of listed entity	Diamines And Chemicals Limited					
Mode of Fund Raising	Public Issues / Rights Issues / Preferential Issues / QIP / Others					
Date of Raising Funds	September 21, 2024					
Amount Raised	50.58 Cr (100% of issue) *					
Report filed for Quarter ended	September 30, 2024					
Monitoring Agency	applicable / not applicable					
Monitoring Agency Name, if applicable	NA					
Is there a Deviation / Variation in use of funds raised	Yes / No					
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	NA					
If Yes, Date of shareholder Approval	NA					
Explanation for the Deviation / Variation	NA					
Comments of the Audit Committee after review	None					
Comments of the auditors, if any	None					
Objects for which funds have been raised and where there has been a deviation, in the following table						
Original Object	Modified Object, if any	Original Allocation (In Rs in Crs)	Modified allocation, if any	Funds Utilised (In Rs in Crs)	Amount of Deviation/Variation for the quarter according to applicable object	Remarks
capital expenditures, working capital requirements, acquisition, investment in technology and for general corporate purpose	NA	50.58	NA	-	-	12.51 crs received up to 26.09.2024 (i.e. 25% of the issue)
Deviation or variation means: (a) Deviation in the object or purposes for which the funds has been raised or (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or (c) Change in the terms of contract referred to in the funds raising documents i.e. prospectus, letter of offer, etc						
*Note: The Company had received In-Principle approval for issue not exceeding 916390 number of convertible warrants at Rs. 552 per warrant. The Company had allotted 906390 convertible warrants on receipt of subscription money Rs. 12.51 crores i.e. 25% of the total Issue, on preferential basis to the investors.						

Hemaxi Pawar
 Company Secretary
 Membership No.: A52581